DEXCOM INC Insider Trading for March 2017
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in DEXCOM INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in DEXCOM INC for March 2017.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | S | 76.25 | 3,987 | 304,006 | 118,874 | 122.9 K to 118.9 K (-3.25 %) |
| Mar 24 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | S | 76.38 | 3,182 | 243,029 | 9,551 | 12.7 K to 9.6 K (-24.99 %) |
| Mar 24 2017 | DXCM | DEXCOM INC | ROPER JESS | SVP, CFO | Sell | S | 75.97 | 2,000 | 151,937 | 8,452 | 10.5 K to 8.5 K (-19.14 %) |
| Mar 21 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Option Exercise | M | 8.79 | 10,000 | 87,900 | 13,649 | |
| Mar 21 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | S | 77.82 | 10,000 | 778,158 | 343,680 | 353.7 K to 343.7 K (-2.83 %) |
| Mar 21 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Buy | M | 8.79 | 10,000 | 87,900 | 353,680 | 343.7 K to 353.7 K (+2.91 %) |
| Mar 16 2017 | DXCM | DEXCOM INC | KAHN BARBARA | Director | Sell | S | 77.36 | 3,000 | 232,080 | 21,304 | 24.3 K to 21.3 K (-12.34 %) |
| Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Option Exercise | M | 7.63 | 7,500 | 57,225 | 0 | |
| Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | S | 77.32 | 3,050 | 235,824 | 82,155 | 85.2 K to 82.2 K (-3.58 %) |
| Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | S | 77.78 | 2,732 | 212,485 | 85,205 | 87.9 K to 85.2 K (-3.11 %) |
| Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | S | 78.07 | 5,194 | 405,506 | 87,937 | 93.1 K to 87.9 K (-5.58 %) |
| Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Buy | M | 7.63 | 7,500 | 57,225 | 93,131 | 85.6 K to 93.1 K (+8.76 %) |
| Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | D | 77.55 | 2,538 | 196,823 | 85,631 | 88.2 K to 85.6 K (-2.88 %) |
| Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | D | 77.55 | 5,473 | 424,434 | 88,169 | 93.6 K to 88.2 K (-5.84 %) |
| Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | D | 77.55 | 1,950 | 151,224 | 93,642 | 95.6 K to 93.6 K (-2.04 %) |
| Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | S | 77.24 | 3,012 | 232,650 | 95,592 | 98.6 K to 95.6 K (-3.05 %) |
| Mar 15 2017 | DXCM | DEXCOM INC | Leach Jacob Steven | SVP, Research & Dev ... | Sell | S | 77.56 | 7,329 | 568,423 | 98,604 | 105.9 K to 98.6 K (-6.92 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | S | 77.74 | 14,400 | 1,119,514 | 10,442 | 24.8 K to 10.4 K (-57.97 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | D | 77.55 | 3,964 | 307,411 | 24,842 | 28.8 K to 24.8 K (-13.76 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | D | 77.55 | 6,694 | 519,124 | 28,806 | 35.5 K to 28.8 K (-18.86 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Buy | J | 78.24 | 12,667 | 991,066 | 35,500 | 22.8 K to 35.5 K (+55.48 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Buy | J | 78.24 | 7,500 | 586,800 | 22,833 | 15.3 K to 22.8 K (+48.91 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Buy | J | 78.24 | 11,834 | 925,892 | 15,333 | 3.5 K to 15.3 K (+338.21 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | D | 77.55 | 6,254 | 485,001 | 34,079 | 40.3 K to 34.1 K (-15.51 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | J | 78.24 | 12,667 | 991,066 | 40,333 | 53 K to 40.3 K (-23.90 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | J | 78.24 | 7,500 | 586,800 | 53,000 | 60.5 K to 53 K (-12.40 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | VALDES JORGE A | CTO | Sell | J | 78.24 | 11,834 | 925,892 | 60,500 | 72.3 K to 60.5 K (-16.36 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | ROPER JESS | SVP, CFO | Sell | D | 77.55 | 5,120 | 397,059 | 46,497 | 51.6 K to 46.5 K (-9.92 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | ROPER JESS | SVP, CFO | Sell | D | 77.55 | 1,948 | 151,069 | 51,617 | 53.6 K to 51.6 K (-3.64 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | ROPER JESS | SVP, CFO | Sell | D | 77.55 | 2,538 | 196,823 | 53,565 | 56.1 K to 53.6 K (-4.52 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Sell | D | 77.55 | 5,813 | 450,802 | 64,664 | 70.5 K to 64.7 K (-8.25 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Sell | D | 77.55 | 2,867 | 222,338 | 70,477 | 73.3 K to 70.5 K (-3.91 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Sell | D | 77.55 | 3,213 | 249,170 | 73,344 | 76.6 K to 73.3 K (-4.20 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Buy | J | 78.24 | 11,000 | 860,640 | 76,557 | 65.6 K to 76.6 K (+16.78 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Buy | J | 78.24 | 6,667 | 521,626 | 65,557 | 58.9 K to 65.6 K (+11.32 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Buy | J | 78.24 | 8,334 | 652,052 | 58,890 | 50.6 K to 58.9 K (+16.48 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Sell | J | 78.24 | 11,000 | 860,640 | 57,486 | 68.5 K to 57.5 K (-16.06 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Sell | J | 78.24 | 6,667 | 521,626 | 68,486 | 75.2 K to 68.5 K (-8.87 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Sell | J | 78.24 | 8,334 | 652,052 | 75,153 | 83.5 K to 75.2 K (-9.98 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | D | 77.55 | 3,208 | 248,782 | 116,033 | 119.2 K to 116 K (-2.69 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | D | 77.55 | 6,694 | 519,124 | 119,241 | 125.9 K to 119.2 K (-5.32 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | D | 77.55 | 3,528 | 273,599 | 125,935 | 129.5 K to 125.9 K (-2.73 %) |
| Mar 14 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Sell | S | 77.71 | 3,200 | 248,672 | 129,463 | 132.7 K to 129.5 K (-2.41 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | D | 77.55 | 3,208 | 248,782 | 97,815 | 101 K to 97.8 K (-3.18 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | D | 77.55 | 3,527 | 273,521 | 101,023 | 104.6 K to 101 K (-3.37 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Sell | D | 77.55 | 6,694 | 519,124 | 104,550 | 111.2 K to 104.6 K (-6.02 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | DOUBLEDAY RICHARD | EVP, Chief Commerci ... | Grant | A | 0.00 | 27,510 | 28 | 111,244 | 83.7 K to 111.2 K (+32.85 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | MOY JEFFREY | SVP, Operations | Grant | A | 0.00 | 21,883 | 22 | 83,487 | 61.6 K to 83.5 K (+35.52 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | D | 77.55 | 6,694 | 519,124 | 122,861 | 129.6 K to 122.9 K (-5.17 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | D | 77.55 | 4,540 | 352,080 | 129,555 | 134.1 K to 129.6 K (-3.39 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Sell | D | 77.55 | 3,824 | 296,553 | 134,095 | 137.9 K to 134.1 K (-2.77 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | Pacelli Steven Robert | EVP, Strategy & Cor ... | Grant | A | 0.00 | 27,510 | 28 | 137,919 | 110.4 K to 137.9 K (+24.92 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Option Exercise | M | 8.85 | 3,000 | 26,550 | 10,939 | |
| Mar 10 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Sell | D | 77.55 | 3,537 | 274,296 | 84,034 | 87.6 K to 84 K (-4.04 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Sell | D | 77.55 | 6,161 | 477,789 | 87,571 | 93.7 K to 87.6 K (-6.57 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Sell | S | 77.67 | 3,000 | 233,002 | 93,732 | 96.7 K to 93.7 K (-3.10 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Buy | M | 8.85 | 3,000 | 26,550 | 96,732 | 93.7 K to 96.7 K (+3.20 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | LISTER JOHN | General Manager, EM ... | Grant | A | 0.00 | 23,134 | 23 | 93,732 | 70.6 K to 93.7 K (+32.77 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | D | 77.55 | 7,927 | 614,744 | 343,680 | 351.6 K to 343.7 K (-2.25 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | D | 77.55 | 15,853 | 1,229,410 | 351,607 | 367.5 K to 351.6 K (-4.31 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Sell | D | 77.55 | 13,211 | 1,024,521 | 367,460 | 380.7 K to 367.5 K (-3.47 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | SAYER KEVIN R | President & CEO | Grant | A | 0.00 | 81,280 | 81 | 380,671 | 299.4 K to 380.7 K (+27.15 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | GREGG TERRANCE H | Executive Chairman | Sell | D | 77.55 | 14,512 | 1,125,414 | 454,559 | 469.1 K to 454.6 K (-3.09 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | GREGG TERRANCE H | Executive Chairman | Sell | D | 77.55 | 1,661 | 128,812 | 469,071 | 470.7 K to 469.1 K (-0.35 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | GREGG TERRANCE H | Executive Chairman | Grant | A | 0.00 | 30,887 | 31 | 470,732 | 439.8 K to 470.7 K (+7.02 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | Balo Andrew K | EVP, Clinical and R ... | Grant | A | 0.00 | 28,761 | 29 | 132,663 | 103.9 K to 132.7 K (+27.68 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | Abbey Donald | EVP Quality | Grant | A | 0.00 | 27,510 | 28 | 82,510 | 55 K to 82.5 K (+50.02 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | Murphy Patrick Michael | VP, Legal Aff & Chf ... | Sell | D | 77.55 | 2,209 | 171,309 | 34,453 | 36.7 K to 34.5 K (-6.03 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | Murphy Patrick Michael | VP, Legal Aff & Chf ... | Sell | D | 77.55 | 1,611 | 124,934 | 36,662 | 38.3 K to 36.7 K (-4.21 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | Murphy Patrick Michael | VP, Legal Aff & Chf ... | Sell | D | 77.55 | 2,216 | 171,852 | 38,273 | 40.5 K to 38.3 K (-5.47 %) |
| Mar 10 2017 | DXCM | DEXCOM INC | Murphy Patrick Michael | VP, Legal Aff & Chf ... | Grant | A | 0.00 | 11,361 | 11 | 40,489 | 29.1 K to 40.5 K (+39.00 %) |
| Mar 08 2017 | DXCM | DEXCOM INC | SKYLER JAY S | Director | Option Exercise | M | 7.31 | 31,890 | 233,116 | 0 | |
| Mar 08 2017 | DXCM | DEXCOM INC | SKYLER JAY S | Director | Sell | S | 78.13 | 31,890 | 2,491,572 | 17,246 | 49.1 K to 17.2 K (-64.90 %) |
| Mar 08 2017 | DXCM | DEXCOM INC | SKYLER JAY S | Director | Buy | M | 7.31 | 31,890 | 233,116 | 49,136 | 17.2 K to 49.1 K (+184.91 %) |